“A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.
According to Noubar Afeyan, founder and CEO of Flagship Pioneering, his company shouldn’t be pigeonholed as a VC firm. ““From day one, our intent was to innovate and create new companies.”
An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.
Former Pfizer exec and current partner at VC firm Polaris Partners Amy Schulman talks about what it takes to lead a pharma startup.
As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company.
Casey Lynch has long had the gut feeling there was more to the cause of Alzheimer’s than beta amyloid and tau proteins. Turns out, she was right.
A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.
The industry veteran talks about leaving Novartis to take care of her sister for a year and how that prepared her for her new job at Lilly.
When Joseph Papa took over Valeant Pharmaceuticals in May 2016, the company was in turmoil. We catch up with Papa and see how he’s coming with what he calls “the turnaround opportunity of a lifetime.”
Recounting what an executive did while on sabbatical wouldn’t normally fit into our editorial model. That is, unless that executive is Richard Bagger, J.D., EVP of corporate affairs and market access for Celgene.
Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.
Camilla Harder Hartvig is SVP of Canada and EMEA for Alexion Pharmaceuticals. Previously she was president, Europe and emerging markets, at Glenmark Pharmaceuticals and also worked for companies such as Allergan, AstraZeneca, and Novartis in various managerial positions.
We reached out to eight experts from biosimilar companies and consulting firms to see which topics they’ve been watching closely throughout 2017 and how they expect these trends will evolve and challenge the industry in 2018.
We hear from 11 women and one man in biopharma. Although we were not aiming for “balance” here — there are plenty of opposing opinions out there already — the sole gender-exception in this group supplies another valuable viewpoint…
Clay Siegall, the founder of Seattle Genetics, explains how his company became an unintentional-startup incubator for Alder BioPharmaceuticals.
The CEO of Seattle Genetics discusses the past, present, and future of some of his company’s partnerships.
The CEO of Seattle Genetics reveals what surprised him about founding a biopharmaceutical company.
Here, I aim to offer some additional ideas for how companies can best describe themselves and their products — and how PR agents, journalists, and others might describe them — by achieving the opposite of hype: clarity.
Rob Wright interviews Kate Merton, head of Johnson & Johnson Innovation’s newly created JLABS in New York City.